1. Amazon in talks with PBMs over pharma supply chain
Amazon is reportedly communicating with pharmacy benefit managers about potential drug contracts.
2. WHO: The world has a serious lack of new antibiotics under development
The world has a severe lack of new antibiotics being developed to combat antimicrobial resistance, according to a recent report by the World Health Organization.
3. Biosimilars are getting approved, but few have hit the market — here’s why
The Food and Drug Administration has approved seven biosimilars drugs since 2015, but only three are on the market.
4. California seeks disciplinary action against UC Los Angeles pharmacy after investigation reveals it distributed drugs with expired ingredients
The California State Board of Pharmacy is pursuing disciplinary action against an off-campus UC Los Angeles pharmacy after an investigation last October revealed the facility compounded drugs with “expired and potentially dangerous ingredients.”
5. Rural hospitals struggle to stock rare disease drugs blocked from 340B discounts
Rural hospitals often struggle to keep expensive rare disease drugs stocked and available for patients, since they must pay full price for the medications through the 340B Drug Discount Program.
More articles on supply chain:
Teva to sell remaining women’s health assets in 2 deals totaling $1.38B
Alaska union-benefits fund sues Abbott over faulty St. Jude defibrillators
Pfizer hits J&J with 1st ever biosimilar antitrust lawsuit: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
